Abstract Redirecting patient’s endogenous T cells to safely and effectively eradicate tumors continues to offer compelling therapeutic opportunities. We found that EVOLVE, a trispecific antibody targeting a tumor-specific antigen together with integrated CD3 activation and CD2 costimulation, led to unique T cell activation profiles. Like the events observed with intact or artificial antigen presenting cells, these trispecific antibodies were sufficient to trigger the formation of a CD2 corolla surrounding the immunological synapse, independent of membrane CD58, on 95% primary human T cells, in a tumor-antigen dependent manner, compared to 20% observed with CD3-matched bispecifics. Trispecific antibodies demonstrated significant functional advantages over conventional bispecific antibodies, with corolla-associated signaling leading to a 1.6-fold amplification of T cell activation events. This resulted in an over 10-fold increase in killing potency against high-antigen-expressing tumor cells and a 20-fold enhancement of killing potency against low-antigen-expressing tumor cells. These findings provide fundamental insights into the CD2 tropism for corolla localization, even when the CD2 and CD3 ligands are covalently linked to each other, confirming the potential for EVOLVE to initiate CD2-costimulatory signaling at the T cell synapse, thereby enhancing the therapeutic efficacy of T cell engagers. Citation Format: Sergio Trombetta, Shengpan Zhang, Tanmay Mitra, Salvatore Valvo, Colleen Brown, Oksana Segreeva, Stella Martomo, Martin Preyer, Jay Fine, Jeremy Myers, Michael Dustin. Pharmacological integration of CD3 and CD2 signaling triggers formation of a CD2 corolla that boosts T cell activation abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5594.
Trombetta et al. (2026) studied this question.